228 related articles for article (PubMed ID: 32239711)
1. Rituximab in late-onset myasthenia gravis is safe and effective.
Sahai SK; Maghzi AH; Lewis RA
Muscle Nerve; 2020 Sep; 62(3):377-380. PubMed ID: 32239711
[TBL] [Abstract][Full Text] [Related]
2. Rituximab treatment of myasthenia gravis: A systematic review.
Tandan R; Hehir MK; Waheed W; Howard DB
Muscle Nerve; 2017 Aug; 56(2):185-196. PubMed ID: 28164324
[TBL] [Abstract][Full Text] [Related]
3. Low-dose rituximab treatment for new-onset generalized myasthenia gravis.
Li H; Huang Z; Jia D; Xue H; Pan J; Zhang M; Shi K; Shi FD; Zhang C
J Neuroimmunol; 2021 May; 354():577528. PubMed ID: 33662696
[TBL] [Abstract][Full Text] [Related]
4. Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis.
Robeson KR; Kumar A; Keung B; DiCapua DB; Grodinsky E; Patwa HS; Stathopoulos PA; Goldstein JM; O'Connor KC; Nowak RJ
JAMA Neurol; 2017 Jan; 74(1):60-66. PubMed ID: 27893014
[TBL] [Abstract][Full Text] [Related]
5. Refractory myasthenia gravis - clinical profile, comorbidities and response to rituximab.
Sudulagunta SR; Sepehrar M; Sodalagunta MB; Settikere Nataraju A; Bangalore Raja SK; Sathyanarayana D; Gummadi S; Burra HK
Ger Med Sci; 2016; 14():Doc12. PubMed ID: 27790079
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis.
Li T; Zhang GQ; Li Y; Dong SA; Wang N; Yi M; Qi Y; Zhai H; Yang L; Shi FD; Yang CS
J Clin Neurosci; 2021 Mar; 85():6-12. PubMed ID: 33581791
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients ≥65 years old.
Doughty CT; Suh J; David WS; Amato AA; Guidon AC
Muscle Nerve; 2021 Dec; 64(6):651-656. PubMed ID: 34378210
[TBL] [Abstract][Full Text] [Related]
8. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria.
Topakian R; Zimprich F; Iglseder S; Embacher N; Guger M; Stieglbauer K; Langenscheidt D; Rath J; Quasthoff S; Simschitz P; Wanschitz J; Windisch D; Müller P; Oel D; Schustereder G; Einsiedler S; Eggers C; Löscher W
J Neurol; 2019 Mar; 266(3):699-706. PubMed ID: 30649616
[TBL] [Abstract][Full Text] [Related]
9. [Rituximab for the treatment of generalised myasthenia gravis: experience in clinical practice].
Martínez-Monte E; Gascón-Giménez F; Domínguez-Morán JA; Láinez-Andres JM
Rev Neurol; 2021 Nov; 73(12):416-420. PubMed ID: 34877644
[TBL] [Abstract][Full Text] [Related]
10. Use and monitoring of low dose rituximab in myasthenia gravis.
Blum S; Gillis D; Brown H; Boyle R; Henderson R; Heyworth-Smith D; Hogan P; Kubler P; Lander C; Limberg N; Pillans P; Prain K; Staples C; Walsh M; McCombe P; Wong R
J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):659-63. PubMed ID: 21071753
[TBL] [Abstract][Full Text] [Related]
11. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.
Hehir MK; Hobson-Webb LD; Benatar M; Barnett C; Silvestri NJ; Howard JF; Howard D; Visser A; Crum BA; Nowak R; Beekman R; Kumar A; Ruzhansky K; Chen IA; Pulley MT; LaBoy SM; Fellman MA; Greene SM; Pasnoor M; Burns TM
Neurology; 2017 Sep; 89(10):1069-1077. PubMed ID: 28801338
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis.
Landon-Cardinal O; Friedman D; Guiguet M; Laforêt P; Heming N; Salort-Campana E; Jouen F; Allenbach Y; Boyer O; Chatenoud L; Eymard B; Sharshar T; Benveniste O
J Neuromuscul Dis; 2018; 5(2):241-249. PubMed ID: 29865089
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximab.
Chan F; Swayne A; Gillis D; Walsh M; Henderson RD; McCombe PA; Wong RC; Blum S
J Neurol Neurosurg Psychiatry; 2019 Aug; 90(8):955-956. PubMed ID: 30455407
[No Abstract] [Full Text] [Related]
14. Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study.
Litchman T; Roy B; Kumar A; Sharma A; Njike V; Nowak RJ
J Neurol Sci; 2020 Apr; 411():116690. PubMed ID: 32028072
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.
Iorio R; Damato V; Alboini PE; Evoli A
J Neurol; 2015 May; 262(5):1115-9. PubMed ID: 25308632
[TBL] [Abstract][Full Text] [Related]
16. Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis.
Roda RH; Doherty L; Corse AM
Neuromuscul Disord; 2019 Jul; 29(7):554-561. PubMed ID: 31296355
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study.
Dos Santos A; Noury JB; Genestet S; Nadaj-Pakleza A; Cassereau J; Baron C; Videt D; Michel L; Pereon Y; Wiertlewski S; Magot A
Eur J Neurol; 2020 Nov; 27(11):2277-2285. PubMed ID: 32526053
[TBL] [Abstract][Full Text] [Related]
18. Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients.
Afanasiev V; Demeret S; Bolgert F; Eymard B; Laforêt P; Benveniste O
Neuromuscul Disord; 2017 Mar; 27(3):251-258. PubMed ID: 28082209
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Efficacy and Safety of Low-Dose Rituximab in Patients with Refractory Myasthenia Gravis.
Ren J; Wang J; Liu R; Jin Y; Guo J; Yao Y; Luo J; Hao H; Gao F
Eur Neurol; 2023; 86(6):387-394. PubMed ID: 37778340
[TBL] [Abstract][Full Text] [Related]
20. Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis.
Brauner S; Eriksson-Dufva A; Hietala MA; Frisell T; Press R; Piehl F
JAMA Neurol; 2020 Aug; 77(8):974-981. PubMed ID: 32364568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]